文献速递血栓与止血

儿童免疫性血小板减少症紧急治疗反应预测因素

Predictors of response to emergent therapies in paediatric immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2025-08-05

该研究比较了511例儿童免疫性血小板减少症(ITP)患者中紧急治疗(ET)有反应与无反应者的临床特征,发现继发性ITP、系统性红斑狼疮、基线直接抗人球蛋白试验(DAT)阳性及高基线IgA水平为静脉注射免疫球蛋白(IVIG)无反应的预测因素。

要点

  • 儿童ITP紧急治疗无反应率高,需识别预测因素。
  • 继发性ITP、系统性红斑狼疮、基线DAT阳性、高基线IgA水平预测IVIG无反应。
  • 未来指南纳入反应预测因素可帮助个体化治疗。

核心结论

  • 继发性ITP、系统性红斑狼疮、基线DAT阳性及高基线IgA水平是儿童ITP患者对IVIG无反应的预测因素。

研究设计与样本

  • 研究比较了儿童ITP患者中紧急治疗有反应与无反应者的临床特征。
  • 队列包含近5年诊断的511例儿童ITP患者。
  • 采用多变量逻辑回归模型识别预测因素。

主要发现

  • 该儿童ITP队列中紧急治疗无反应率高。
  • 继发性ITP、系统性红斑狼疮、基线DAT阳性及高基线IgA水平为IVIG无反应的预测因素。

关键数值与推荐

  • 多变量逻辑回归模型识别出继发性ITP、系统性红斑狼疮、基线DAT阳性及高基线IgA水平为IVIG无反应的预测因素。

临床怎么用

  • 作者认为,未来管理指南纳入反应预测因素可帮助为每位患者个体化治疗,提高反应率以确保减少出血相关疾病并避免不必要的副作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emergent therapies (ET), which include intravenous immunoglobulin (IVIG), corticosteroids and intravenous anti-Rho(D) immunoglobulin, are used to treat acute episodes of bleeding in children with immune thrombocytopenia (ITP). There are currently no known biomarkers or clinical features predictive of treatment response to any specific ET. Thus, the treatment of ITP remains largely trial and error, exposing patients to potentially ineffective medications, which are often expensive and associated with adverse effects. We therefore sought to identify the predictors of treatment response through comparison of clinical characteristics in paediatric patients with ITP responsive to ET versus those non-responsive to ET. We identified high rates of non-response to ET in our cohort of 511 children diagnosed with ITP over a recent 5-year period. Through a multivariable logistic regression model, we identified the presence of secondary ITP, the presence of systemic lupus erythematosus, a positive baseline direct antiglobulin test (DAT) and a high baseline IgA level as predictors of non-response to IVIG. In the future, management guidelines that incorporate predictors of response could help individualize treatment for each patient, achieving better response rates that ensure less bleeding-related morbidity and avoid unnecessary side effects.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. O'Farrell C, Luckie TM, Willis MJ, et al. Predictors of response to emergent therapies in paediatric immune thrombocytopenia. Br J Haematol. 2025. PMID: 40762147. doi:10.1111/bjh.70064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。